Meeting
2023 ASCO Genitourinary Cancers Symposium
Safety and quality of life analyses of apalutamide plus active surveillance vs active surveillance alone for low, intermediate risk prostate cancer.
Authors
Gwenaelle Gravis
Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Universite, CRCM, Marseille, France
Gwenaelle Gravis , Patrick Sfumato , Guillaume Ploussard , Pierre-Henri Savoie , Matthieu Durand , Romain Mathieu , Xavier Rebillard , Geraldine Pignot , Jean-Baptiste Beauval , Youness Ahallal , Mathilde Guerin , Laurys Boudin , Sebastien Crouzet , Naji Salem , Cecile Vicier , Jean-Marie Boher , Patricia Marino , Jochen Walz , Sebastien Vincendeau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03088124
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 352)
DOI
10.1200/JCO.2023.41.6_suppl.352
Abstract #
352
Poster Bd #
M10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.
First Author: Nicholas George Nickols
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression.
First Author: Phillip M. Kemp Bohan
Poster
2014 ASCO Annual Meeting
A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.
First Author: Michael J. Morris
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.
First Author: Lauren Lenz